Asterias Biotherapeutics Inc (AST) Short Interest Update
Asterias Biotherapeutics Inc (NYSE:AST) was the recipient of a large increase in short interest in October. As of October 13th, there was short interest totalling 2,800,014 shares, an increase of 8.6% from the September 29th total of 2,577,169 shares. Based on an average daily volume of 232,873 shares, the days-to-cover ratio is presently 12.0 days. Currently, 10.2% of the company’s stock are short sold.
A number of hedge funds have recently modified their holdings of AST. Family Management Corp boosted its stake in Asterias Biotherapeutics by 15.6% in the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 6,416 shares in the last quarter. California State Teachers Retirement System boosted its stake in Asterias Biotherapeutics by 4.6% in the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,100 shares in the last quarter. Teachers Advisors LLC boosted its stake in Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 6,714 shares in the last quarter. Finally, State Street Corp boosted its stake in Asterias Biotherapeutics by 24.1% in the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock valued at $1,169,000 after acquiring an additional 63,773 shares in the last quarter.
A number of analysts have recently commented on the company. HC Wainwright set a $12.00 price target on Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Zacks Investment Research raised Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, July 17th.
Shares of Asterias Biotherapeutics (NYSE AST) traded down 5.66% during mid-day trading on Tuesday, hitting $2.50. The stock had a trading volume of 270,116 shares. Asterias Biotherapeutics has a 52-week low of $2.50 and a 52-week high of $5.80. The company’s 50 day moving average is $3.21 and its 200-day moving average is $3.31. The stock’s market cap is $124.95 million.
Asterias Biotherapeutics (NYSE:AST) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $1.25 million. Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. On average, equities research analysts anticipate that Asterias Biotherapeutics will post ($0.61) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/24/asterias-biotherapeutics-inc-ast-short-interest-update-2.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.